Bergen, Norway, 2 October 2024: Today, Lifecare ASA (LIFE), a clinical stage
medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), can announce that we have completed a successful production
based on automated processes of our glucose sensor, Sencell.

Reference is made to the Q2 report when the company described the necessary
steps of preparations towards automated production. Lifecare' manufacturing
department has successfully executed production of Sencell sensors at our
laboratory in Reutlingen, based on automated processes. These processes will
now be repeated at our production facilities in Mainz.

- At the end of the 1st quarter, we reached our goal of successful pilot
production of Sencell. We have now automated the most critical steps in the
production process, transitioning from partially hand-made sensors towards
automated production. The achievement demonstrates our ability to conduct
automated production of glucose monitoring sensors for both humans and pets,
says CEO Joacim Holter.

The sensors that have been produced are now subject to internal in vitro
sensor quality control and bacteriological testing. Subject to quality
approval, the newly manufactured sensors will be used in the second phase of
the longevity study organized by Lifecare Veterinary, starting in the next few
weeks.

The automated production process involves two key steps. The first step is a
sophisticated deposition process conducted within a Scanning Electron
Microscope (SEM), using customized software to produce the Sencell sensor. The
second step involves an automated process for filling Lifecare's proprietary
and patented glucose-reactive chemical solution into the nanosized chambers of
the sensors. This step also includes applying nano-porous membranes to seal
the chambers after filling. To accomplish this, Lifecare's production team
utilizes advanced and customized equipment for automated production processes.

- We are very pleased that our innovative glucose sensor, which has a complex
structure, can also be produced based on the automatically processes with the
equipment that we have invested in and spent time adapting to our production
purpose. While the current automated production is not at a volume scale, it
significantly enhances the efficiency of the process and increases sensor
output. We will now repeat the production based on automated processes at our
pilot manufacturing unit in Mainz and continue the process improvements
towards scalable production, says Holter.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42